Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., Natural product-based Lifespan extension therapy: 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 22/April/2014, 7.34 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. This study suggests, for the first time, that 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ), by increasing the expression of their target gene, they may suppress the expression of AT1R. And, thereby, they may (1) decrease blood pressure; and (2) extend the lifespan of an individual. Thus, pharmacological formulations encompassing “3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) or its analogues” may be used to extend the life-span of an individual.
Undisclosed information: How 3-caffeoyl, 4-dihydrocaffeoylquinic acid (CDCQ) suppresses the expression of angiotensin II type I receptor (AT1R)
